HC Wainwright Issues Pessimistic Estimate for SNTI Earnings

Senti Biosciences, Inc. (NASDAQ:SNTI) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for Senti Biosciences in a report issued on Friday, May 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.33) for the quarter, down from their previous estimate of ($0.14). The consensus estimate for Senti Biosciences’ current full-year earnings is ($1.03) per share. HC Wainwright also issued estimates for Senti Biosciences’ Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.72) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at ($0.20) EPS.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.22. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Tuesday, April 21st. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Chardan Capital lifted their price objective on Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Senti Biosciences has an average rating of “Moderate Buy” and a consensus price target of $8.75.

Senti Biosciences Price Performance

Shares of NASDAQ:SNTI opened at $0.94 on Tuesday. Senti Biosciences has a 1-year low of $0.77 and a 1-year high of $3.88. The business has a fifty day moving average price of $0.95 and a 200-day moving average price of $1.20. The company has a market capitalization of $29.28 million, a PE ratio of -0.49 and a beta of 2.09.

Institutional Investors Weigh In On Senti Biosciences

Large investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at about $40,000. Virtu Financial LLC purchased a new position in Senti Biosciences in the 4th quarter worth approximately $46,000. Citadel Advisors LLC purchased a new stake in shares of Senti Biosciences during the 3rd quarter worth approximately $117,000. Geode Capital Management LLC raised its holdings in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Senti Biosciences during the 2nd quarter worth approximately $1,883,000. 25.70% of the stock is currently owned by institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.